101
Views
6
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer

, , , , , , , , & show all
Pages 203-209 | Received 19 Feb 2015, Accepted 08 Apr 2015, Published online: 14 Jul 2016

References

  • Urmancheeva AF, Kutusheva GF, Ulrich EA. Ovarian tumors (symptoms, diagnostics and treatment). Saint-Petersburg: Publishing House N-L; 2012; p. 68. (in Russian).
  • Zhu Y, Hanna N, Boutros C, Alexander HR Jr.. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol. 2013;4(1):62–71.
  • Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.
  • Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.
  • Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
  • Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macrì A, et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 2011;37(1):4–9.
  • Belyaev AM, Bagnenko SF, Ruchlyada NV. Intraperitoneal chemotherapy of malignant tumors of the abdominal cavity. Saint-Petersburg: ELBI-SPb; 2007; p. 254. (in Russian).
  • González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2(2):68–75.
  • Stukov AN, Gershanovich ML, Blank MA, et al. Antitumor drugs. Saint-Petersburg: NIKA; 2011; p. 656. (in Russian).
  • Gershanovich ML, Filov VA, Cotova DG, Stukov AN, Sokolov IuN, Ivin BA. Results of phase II clinical study of antitumor drug dioxadet. Vopr Onkol. 1998;44(2):216–20, (in Russian).
  • Pogosyanz EE, Prigozhina EL, Egolina NA. Transplanted ascitic rat ovarian tumor. Vopr Onkol. 1962;8(11):29–36, (in Russian).
  • Beliaeva OA, Bespalov VG, Senchik KIu, Kireeva GS, Stukov AN, Aristova VA, et al. Experimental technology of chemoperfusion treatment of peritoneal carcinomatosis from ovarian cancer. Vopr Onkol. 2014;60(1):71–8, (in Russian).
  • Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1:87–93.
  • Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999;15:79–107.
  • Bespalov VG, Beliaeva OA, Kireeva GS, Senchik KIu, Stukov AN, Aristova VA, et al. Antitumor activity of dioxadet in intraperitoneal chemoperfusion treatment of advanced ovarian cancer: experimental study. Vopr Onkol. 2014;60(2):76–80.
  • Bespalov VG, Belyaeva OA, Kireeva GS, Senchik KY, Stukov AN, Belyaev AM. Intraperitoneal chemoperfusion treatment of advanced ovarian cancer with dioxadet compared to cisplatin in experimental settings. Sib J Oncol. 2014;62(1):14–8, (in Russian).
  • Ahmed K, Zaidi SF. Treating cancer with heat: hyperthermia as promising strategy to enhance apoptosis. J Pak Med Assoc. 2013;63:504–8.
  • Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423–32.
  • Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A. Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol. 2008;134:1143–9.
  • Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–7.
  • Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:143–7.
  • Reich G, Mapara MY, Reichardt P. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001;27:525–9.
  • Straka C, Oduncu F, Hinke A, Einsele H, Drexler E, Schnabel B, et al. Responsiveness to G-CSF before leucopenia predicts defense to infection in high-dose chemotherapy recipients. Blood. 2004;104:1989–94.
  • Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, et al. Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents. 2006;20:29–35.
  • Tavares-Murta BM, Murta EFC. Systemic leukocyte alterations in cancer and their relation to prognosis. Open Cancer J. 2008;2:53–8.
  • Benson AB 3rd, Read TR, Goebel SL, Koeller JM, Tormey DC. Correlations between leukocyte count and absolute granulocyte count in patients receiving cancer chemotherapy. Cancer. 1985;56:1350–5.
  • Michael M, Goldstein D, Clarke SJ, Milner AD, Beale P, Friedlander M, et al. Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer. 2006;6:297–304.
  • Tavares-Murta BM, Mendonca MA, Duarte NL. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer. 2010;20:1154–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.